Literature DB >> 30826989

Amelioration of Lipopolysaccharide-Induced Nephrotic Proteinuria by NFAT5 Depletion Involves Suppressed NF-κB Activity.

Shubo Zhai1, Meina Li2, Baichao Sun1, Yanyan Han3.   

Abstract

Idiopathic nephrotic syndrome (INS) is characterized by proteinuria, in which podocyte dysfunction associated with NF-κB-mediated inflammation plays an important role. The nuclear factor of activated T cells 5 (NFAT5) has been shown to enhance NF-κB activity. However, whether NFAT5 is associated with proteinuria remains uncharacterized. NFAT5 is upregulated in the glomeruli in lipopolysaccharide (LPS)-induced mouse nephrotic proteinuria, as well as in LPS-treated podocytes in vitro. In addition, NFAT5 depletion improves filtration barrier function of LPS-treated podocytes in vitro. Mechanistically, NFAT5 depletion suppresses NF-κB activation and downstream proinflammatory reaction in LPS-treated podocytes, and moreover, NF-κB inhibition improves filtration barrier function of LPS-treated podocytes, suggesting that the suppressed NF-κB activity at least partly accounts for NFAT5 depletion-improved filtration barrier function. Furthermore, in vivo, depletion of NFAT5 suppresses NF-κB activity and ameliorates nephrotic proteinuria in LPS-treated mice. These findings suggest a protective role of NFAT5 depletion against LPS-induced nephrotic proteinuria and relate it to the suppression of NF-κB activity.

Entities:  

Keywords:  NF-κB; NFAT5; idiopathic nephrotic syndrome; lipopolysaccharide; nephrotic proteinuria

Mesh:

Substances:

Year:  2019        PMID: 30826989     DOI: 10.1007/s10753-019-00993-4

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  3 in total

Review 1.  miRNA-486-5p: signaling targets and role in non-malignant disease.

Authors:  Adrianna Douvris; Jose Viñas; Kevin D Burns
Journal:  Cell Mol Life Sci       Date:  2022-06-22       Impact factor: 9.207

Review 2.  The evolving role of TonEBP as an immunometabolic stress protein.

Authors:  Soo Youn Choi; Whaseon Lee-Kwon; Hyug Moo Kwon
Journal:  Nat Rev Nephrol       Date:  2020-03-10       Impact factor: 28.314

3.  An Integration of Network Pharmacology and Experimental Verification to Investigate the Mechanism of Guizhi to Treat Nephrotic Syndrome.

Authors:  Dan He; Qiang Li; Guangli Du; Guofeng Meng; Jijia Sun; Shaoli Chen
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.